10.30-11.15 Registration

11.15-11.30 Opening remarks
Filippo Drago (Catania)

11.30-12.30 Opening lecture (introduced by Filippo Drago)
Depression in schizophrenia: new perspectives for the treatment
Stuart Montgomery (London)

12.30-13.00 Welcome reception

Parco degli Aragonesi Hotel - Viale Kennedy, 2 (Catania)

Psychotic disorders: epidemiology and genetics

Moderator: Alessandro Rossi (L’Aquila)

16.00-17.00  Psychotic disorders: epidemiology and risk factors
Mauro Carta (Cagliari)

17.00-18.00 The genetics of bipolar spectrum disorders
Alessandro Serretti (Rome)
  
18.00-18.30 Discussion

18.30-19.30 Genetics of schizophrenia: new insights from new approaches
Massimo Gennarelli (Brescia)

19.30-19.40 Questionnaire

Schizophrenia: animal models
Introduced and moderated by Marco Riva (Italy)

10.00-11.00 Overview on animal models of schizophrenia
Josè Borrell (Spain)

11.00-12.00 Neural basis of psychosis-related behaviour in the infection model of schizophrenia
Joram Feldon (Switzerland)

12.00-12.30 Discussion

12.30-13.30 Sponsored lecture
  
Schizophrenia: from diagnosis to long-term treatment
Introduced and moderated by Claudio Mencacci (Italy)

16.00-17.00 Factors affecting long-term outcome in schizophrenia
Alessandro  Rossi (Italy)

17.00-18.00 Treatments affecting long-term outcomes in schizophrenia
Roberto Cavallaro (Italy)

18.00-18.30 Discussion

18.30-19.30 Special Lecture:
Neurodegeneration in Schizophrenia: implications for the treatment
Hilleke Hulshoff Pol (The Netherlands)
 
19.30-19.40 Questionnaire

Neurobiology of schizophrenia 
Introduced and moderated by Giorgio Racagni (Italy)

10.00-11.00 Glutamatergic system in the pathogenesis of schizophrenia
Marco Riva (Italy)

11.00-12.00 Metabotropic glutamate receptors as new therapeutic targets for the treatment of schizophrenia
Ferdinando Nicoletti (Italy)

12.00-13.00 Cholinergic system in schizophrenia
Giancarlo Pepeu (Italy)

13.00-13.30 Discussion
                   
Cognitive function in schizophrenia: new insights
Introduced and moderated by Giovanni Biggio (Italy)

16.00-17.00 Cognitive dysfunctions as endophenotypes of schizophrenia: neurobiological correlates
Silvana Galderisi (Italy)

17.00-18.00 Cognitive impairment and long-term outcome in schizophrenia
Eugenio Aguglia (Italy)
                       
18.00-18.30 Discussion

18.30-19.30 Special Lecture:
Cognitive effects of antipsychotic drugs
Michael Davidson (Israel)

19.30-19.40 Questionnaire

Drug discovery in schizophrenia
Introduced and moderated by Pier Luigi Canonico (Italy)

10.00-11.00 Searching for new pharmacological targets in schizophrenia
Andrea De Bartolomeis (Italy)

11.00-12.00 New approaches for antipsychotic drug development
Luca Pani (Italy)

12.00-12.30 Discussion

12.30-13.30 Sponsored lecture
                       
Pharmacological treatment of schizophrenia
Introduced and moderated by Mauro Mauri (Italy)

16.00-17.00 Second-generation versus first-generation antipsychotic drugs for schizophrenia: which evidence ?
Edoardo Spina (Italy)

17.00-18.00 Neuroimaging and response to treatment with antipsychotics in schizophrenia
Alessandro Bertolino (Italy)

18.00-18.30 Discussion

18.30-19.30 Special Lecture:
Subjective well-being and quality of life under antipsychotic treatment
Dieter Naber (Germany)

19.30-19.40 Questionnaire

Safety of antipsychotics: from pre-clinical evidence to regulatory restrictions
Introduced and moderated by Dieter Naber (Germany)

10.00-11.00 Cardiovascular risks of antipsychotic treatment
Milou-Daniel Drici (France)

11.00-12.00 Antipsychotic drugs and the risk of cerebrovascular events: which evidence ?
Emilio Sacchetti (Italy)

12.00-12.30 Discussion

12.30-13.30 Sponsored lecture

Bipolar disorder: from diagnosis to long-term treatment
Introduced and moderated by Edoardo Spina (Italy)

16.00-17.00 Bipolar depression: diagnostic guidelines and treatment options
Mauro Mauri (Italy)

17.00-18.00 Mixed states: clinical subtyping and implications for the treatment
Athanasios Koukopoulos (Italy)

18.00-18.30 Discussion

18.30-19.30 Special lecture:
Treating mania and managing long-term treatment of bipolar disorder
Siegfried Kasper (Austria)

19.30-19.40 Questionnaire

Bipolar disorder: neurobiology and neuropharmacology
Introduced and moderated by Siegrief Kasper (Austria)

10.00-11.00 Neurobiological trait abnormalities in bipolar disorder
Sophia Frangou (United Kingdom)

11.00-12.00 Molecular mechanisms underlying mood stabilizers efficacy: lessons from lithium
Robert Belmaker (Israel)

12.00-12.30 Discussion

12.30-13.30 Sponsored lecture
                       
Psychosis in neurological disorders: from diagnosis to treatment
Introduced and moderated by Giovanni Gambassi (Italy)

16.00-17.00 Psychotic disorders in epilepsy: etiology, clinical features, and therapeutic implications
Riccardo Torta (Italy)

17.00-18.00 Psychosis  in Parkinson’s disease : from diagnosis to treatment 
Mario Zappia (Italy)

18.00-18.30 Discussion

18.30-19.30 Treatment of behavioural and psychological symptoms of dementia: which strategies?
Peter De Deyn (Belgium)

19.30-19.40 Questionnaire

Use of antipsychotics in special populations
Introduced and moderated by Donatella Marazziti (Italy)

10.00-11.00    Use of antipsychotics in children and adolescents: assessing efficacy and safety
Alessandro Zuddas (Italy)

11.00-12.00 Efficacy and safety of antipsychotics in the elderly: which evidence ?
Giovanni Gambassi (Italy)

12.00-12.30 Discussion
 
12.30-13.30 Sponsored lecture

Psychotic disorders and comorbidity
Introduced and moderated by Joseph Zohar (Israel)

16.00-17.00 Pseudoneurotic psychosis: behind the mask
Giovanni Muscettola (Italy)

17.00-18.00 Comorbid substance use disorders in psychoses
Massimo Clerici (Italy)

18.00-18.30 Discussion

18.30-19.30 Special lecture
Schizo-obsessive disorder: clinical characteristics and treatment
Abraham Weizman (Israel)

19.30-19.45 Closing remarks
Filippo Drago (Italy)

19.45-19.55 Questionnaire